Epizyme: Ipsen Completes Acquisition of Epizyme Expanding Its Portfolio in Oncology
Ipsen (Euronext: IPN; ADR: IPSEY) today announced the closing of the definitive merger agreement under which Ipsen has acquired Epizyme, Inc. (Epizyme).
Read full article »
Epizyme is a Massachusetts-based biopharmaceutical company that develops and commercializes novel epigenetic medicines for the treatment of cancer.
Read more